Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.

Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. · 2020

Read Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. by Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7192386.txt.

Introduction

Jarvis and co-authors review which metabolic traits predict severe liver disease in fatty liver patients. Their analysis appeared in PLoS Medicine. Non-alcoholic fatty liver disease is a leading cause of chronic liver illness worldwide. Most people with it never develop cirrhosis or liver cancer. Spotting the minority at real risk is the clinical challenge.

The team pooled population studies on risk factors such as diabetes and high blood pressure. Evidence on blood pressure was mixed across studies. Some large linkage studies tied diagnosed hypertension to later severe liver outcomes. Others found weak or negative links after adjustment. The review shows how uneven the prediction evidence remains. Doctors get a clearer view of which patients need closer follow-up.

Catalog record

CREATORJarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7192386

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies By Helen Jarvis, Dawn Craig, Robert Barker, Gemma Spiers, Daniel Stow, Quentin M. Anstee, Barbara Hanratty, Amit Singal Published in: PLoS Medicine DOI: 10.1371/journal.pmed.1003100 ABSTRACT Background Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide. Many individuals have risk factors associated with NAFLD, but the majority do not develop advanced liver disease: cirrhosis, hepatic decompensation, or hepatocellular carcinoma. Identifying people at high risk of experiencing these complications is important in order to prevent disease progression. This review synthesises the evidence on metabolic risk factors and their potential to predict liver disease outcomes in the general population at risk of NAFLD or with diagnosed NAFLD. Methods and findings We conducted a systematic review and meta-analysis of population-based cohort studies. Databases (including MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov) were searched up to 9 January 2020. Studies were included that reported severe liver disease outcomes (defined as liver cirrhosis, complications of cirrhosis, or liver-related death) or advanced fibrosis/non-alcoholic steatohepatitis (NASH) in adult individuals with metabolic risk factors, compared with individuals with no metabolic risk factors. Cohorts selected on the basis of a clinically indicated liver biopsy were excluded to better reflect general population risk. Risk of bias was assessed using the QUIPS tool. The results of similar studies were pooled, and overall estimates of hazard ratio (HR) were obtained using random-effects meta-analyses. Of 7,300 unique citations, 22 studies met the inclusion criteria and were of sufficient quality, with 18 studies contributing data suitable for pooling in 2 random-effects meta-analyses. Type 2 diabetes mellitus (T2DM) was associated with an increased risk of incident severe liver disease events (adjusted HR 2.25, 95% CI 1.83–2.76, p < 0.001, I2 99%). T2DM data were from 12 studies, with 22.8 million individuals followed up for a median of 10 years (IQR 6.4 to 16.9) experiencing 72,792 liver events. Fourteen studies were included in the meta-analysis of obesity (BMI > 30 kg/m2) as a prognostic factor, providing data on 19.3 million individuals followed up for a median of 13.8 years (IQR 9.0 to 19.8) experiencing 49,541 liver events. Obesity was associated with a modest increase in risk of incident severe liver disease outcomes (adjusted HR 1.20, 95% CI 1.12–1.28, p < 0.001, I2 87%). There was also evidence to suggest that lipid abnormalities (low high-density lipoprotein and high triglycerides) and hypertension were both independently associated with incident severe liver disease. Significant study heterogeneity observed in the meta-analyses and possible under-publishing of smaller negative studies are acknowledged to be limitations, as well as the potential effect of competing risks on outcome. Conclusions In this review, we observed that T2DM is associated with a greater than 2-fold increase in the risk of developing severe liver disease. As the incidence of diabetes and obesity continue to rise, using these findings to improve case finding for people at high risk of liver disease will allow for effective management to help address the increasing morbidity and mortality from liver disease. Trial registration PROSPERO CRD42018115459. INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, with an estimated population prevalence rate of up to 30% in Europe [1]. Progressive liver disease is asymptomatic and usually diagnosed late, at the stage of decompensated cirrhosis, when intervention is less effective and mortality rates are high. Most people with NAFLD will not develop progressive disease (advanced fibrosis/cirrhosis), but recent guidelines have stressed the importance of identifying the minority that will [2]. Data from biopsy studies have shown that the histological staging of liver fibrosis is one of the most important prognostic factors in NAFLD. Advanced fibrosis is associated with severe liver-related outcomes and increased mortality [3,4]. Without undertaking a biopsy, advanced liver disease can be ruled out with acceptable accuracy using non-invasive biomarkers or simple clinical scores [5,6]. However, validation of these methods in unselected populations is limited. Furthermore, in settings where the pretest probability of advanced fibrosis is low, the positive predictive value of non-invasive tests will fall and lead to many false positives [7]. This highlights a need to clearly define the at-risk population before employing these tests. Case finding for advanced liver disease amongst adults with type 2 diabetes mellitus (T2DM) or metabolic syndrome is recommended by the European Association for the Study of the Liver (for those aged over 50 years) and the American Diabetes Association [2,8]. Ongoing studies are providing evidence for the clinical effectiveness and cost-effectiveness of risk-factor-based case finding for NAFLD in unselected populations [9–11]. However, the high and rising prevalence of risk factors for NAFLD means that the introduction of such programmes at scale will be costly, and neither the UK National Institute for Health and Care Excellence (NICE) nor the American Association for the Study of Liver Diseases has recommended case finding in primary care in their latest NAFLD guidelines [12,13]. In the absence of proactive case finding and assessment of high-risk individuals, case ascertainment is inconsistent and largely opportunistic, based on chance findings of abnormal blood tests or imaging carried out for other purposes. The current approach will not identify those at most risk. In many care settings, this means diagnosis late in the disease natural history, with limited scope for effective intervention [14]. In order to develop community-based strategies for earlier, targeted detection of liver disease, a good understanding is needed of which metabolic risk factors best predict severe NAFLD outcomes and advanced fibrosis. Research evidence published up until 2015 was synthesised to underpin the UK NICE guidelines [12], and this synthesis highlighted a paucity of evidence. Since then, several studies from large population cohorts have been published. In addition, the NICE review did not include all relevant outcomes. Cirrhosis and liver-related mortality outcomes were omitted, though natural history studies suggest that it is reasonable to assume that people who develop liver cirrhosis or die from liver disease will have passed through the stage of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis. To address this gap in our understanding, we conducted an updated systematic review of published observational studies including all relevant outcomes. The aim was to synthesise evidence on which of the metabolic risk factors, or combination of risk factors, can best predict incident severe liver disease outcomes or NASH/advanced fibrosis in the general population at risk of NAFLD or with diagnosed NAFLD. METHODS Registration of review protocol The protocol for this review was registered in advance with PROSPERO (International Prospective Register of Systematic Reviews; CRD42018115459). Types of studies and inclusion and exclusion criteria Original studies were included if they were observational, prospective, or retrospective studies that reported either (1) severe liver disease outcomes (cirrhosis, complications of cirrhosis, or liver-related death) or (2) NASH/advanced fibrosis in adults (≥18 years old) with metabolic risk factors as compared with adult individuals without metabolic risk factors. Metabolic risk factors were defined as those included in the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) definition [15], with the addition of BMI > 30 kg/m2 as the most commonly measured obesity marker, assessed as individual risk factors or in combination, making up the

Read the complete text